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Abstract
Objective: To evaluate whether the clinical benefit and relapse rates in anti-
muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the
protocol of rituximab followed. Methods: This retrospective multicentre study
in patients with MuSK MG compared three rituximab protocols in terms of
clinical status, relapse, changes in treatment, and adverse side effects. The pri-
mary effectiveness endpoint was clinical relapse requiring a further infusion of
rituximab. Survival curves were estimated using Kaplan–Meier methods and
survival analyses were undertaken using Cox proportional-hazards models.
Results: Twenty-five patients were included: 11 treated with protocol 4 + 2
(375 mg/m2/4 weeks, then monthly for 2 months), five treated with protocol
1 + 1 (two 1 g doses 2 weeks apart), and nine treated with protocol 4
(375 mg/m2/4 weeks). Mean follow-up was 5.0 years (SD 3.3). Relapse occurred
in 18.2%, 80%, and 33.3%, and mean time to relapse was 3.5 (SD 1.5), 1.1 (SD
0.4), and 2.5 (SD 1.4) years, respectively. Based on Kaplan–Meier estimates,
patients treated with protocol 4 + 2 had fewer and later relapses than patients
treated with the other two protocols (log-rank test P = 0.0001). Patients treated
with protocol 1 + 1 had a higher risk of relapse than patients treated with pro-
tocol 4 + 2 (HR 112.8, 95% CI, 5.7–2250.4, P = 0.002). Patients treated with
protocol 4 showed a trend to a higher risk of relapse than those treated with
protocol 4 + 2 (HR 9.2, 95% CI 0.9–91.8, P = 0.059). Interpretation: This
study provides class IV evidence that the 4 + 2 rituximab protocol has a lower
clinical relapse rate and produces a more durable response than the 1 + 1 and
4 protocols in patients with MuSK MG.
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Introduction
Myasthenia gravis (MG) is an autoimmune disease caused
by antibodies to antigens of the postsynaptic neuromus-
cular junction and clinically characterized by fatigable
muscle weakness.1–5 Approximately, 5% of MG patients
have autoantibodies against muscle-specific kinase
(MuSK),6,7 and the frequency is higher if an IgG-specific
MuSK-cell-based assay is used to detect these antibodies.8
MuSK antibody titers are mainly of the IgG4 subclass and
considered to correlate with patients’ clinical status.9,10
Patients with MuSK MG often present early, severe bulbar
and respiratory involvement. Furthermore, they have a
poorer response to acetylcholine esterase inhibitors, stan-
dard immunosuppressant therapies, and intravenous
immunoglobuline than MG patients without MuSK.10 For
these reasons, the need for an efficient drug to treat
patients with MuSK MG has long been awaited.
Rituximab, a monoclonal antibody that targets the
CD20 antigen in B cells, was first used to treat non-
Hodgkin’s B-cell lymphoma.11–13 However, it later
emerged as a highly effective tool to manage autoimmune
diseases.14,15 As autoreactive B cells have a clear patho-
genic role in the development of MG, rituximab has been
used in drug-resistant MG patients and several authors
have described its benefits.16–20 Rituximab has proven to
be more effective and to have a longer clinical benefit in
patients with antibodies against MuSK17,20 than in
patients with anti-acetylcholine receptor (AChR)-positive
MG.
Rituximab has also shown to be a remarkably effective
drug in other IgG4-mediated diseases of the central and
peripheral nervous system and connective tissue of the
skin or kidneys, such as CIDP with anti-Contactin-1 and
anti-Neurofascin-155 antibodies,21–23 pemphigus,24 mem-
branous glomerulonephritis,25 and LGI1 limbic encephali-
tis.26–28 All IgG4-mediated disorders seem to share
similarities in epitope binding, human leukocyte antigen
associations, disease mechanism, and underlying etiology,
thus explaining the extraordinary response to rituximab
observed in all such disorders.29
We previously reported the benefits of rituximab in a
large series of drug-resistant patients (11 AChR-positive
MG and 6 MuSK-positive MG). Remarkably, all six
patients with MuSK MG achieved minimal manifestations
(MM) or a better Myasthenia Gravis Foundation of
America post-intervention status (MGFA PIS), and no
additional infusions were required during a 31-month fol-
low-up (4–60). The protocol we used was 375 mg/m2
weekly for 4 weeks, then monthly for 2 months (4 + 2).17
Infusion protocols for rituximab in autoimmune dis-
orders14,17–25,30 differ, and no protocol has yet been
established for rituximab in MuSK MG. We wondered
whether our treatment regimen contributed to the
excellent long-term outcome of MuSK MG. Here, we
describe the clinical follow-up in 25 patients with
MuSK MG treated with different infusion protocols of
rituximab. We report the clinical effectiveness, adverse
effects, and differences in clinical outcomes in patients
treated with the three most commonly used rituximab
treatment protocols.
Methods
Patients and clinical evaluation
In this multicentre, retrospective observational study, we
included all patients with MuSK MG treated with ritux-
imab at 11 hospitals in Spain between January 1, 2006
and March 31, 2016. We collected demographic and clini-
cal data at onset and during follow-up. Patients were fol-
lowed until November 30, 2017. To assess the clinical
response, the MGFA PIS was determined periodically, and
relapse rate and changes in treatment were recorded. The
primary effectiveness endpoint was clinical relapse requir-
ing a further infusion of rituximab. Safety was evaluated
based on the effects of rituximab treatment on mortality
and morbidity.
Treatment protocol
The standard treatment protocol for patients with MuSK
MG is first-line prednisone and second-line immunosup-
pressors (azathioprine/mycophenolate followed by cyclos-
porine) if the response is not adequate or if the dose of
prednisone required is higher than 40 mg every other
day. Patients were considered drug-resistant when no
significant clinical improvement was achieved after pred-
nisone and at least two second-line immunosuppres-
sants.31 Patients with MGFA IV or V and no response to
prednisone were treated with rituximab as a second-line
drug in accordance with our previous results.17 Rituximab
was administered following one of three protocols:
(4 + 2) 375 mg/m2 every week for four consecutive weeks
and then monthly for the next 2 months; (1 + 1) two 1 g
doses separated by 2 weeks; and (4) 375 mg/m2 every
week for four consecutive weeks. Rituximab re-infusions
were administered only if patients relapsed. A relapse was
defined as the reappearance of myasthenic symptoms that
limited daily activity.
Protocol approval and patients’ informed
consent
Informed consent was obtained from all patients and the
study was approved by the ethics committees at all
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participating hospitals. Permission for compassionate use
of rituximab was given by the Spanish Ministry of
Health.
Statistical analysis
A descriptive data analysis was performed. Demographic
characteristics are reported as means and standard devia-
tions (SD) for quantitative variables and as percentages
for categorical variables. Differences between patient sub-
groups in baseline characteristics were evaluated using
ANOVA to compare categorical variables and the Mann–
Whitney U test to compare quantitative variables. Log-
rank tests were used to compare Kaplan–Meier estimates
for survival curves for the three treatment groups in a
time-to-first-event analysis. Hazard ratios and 95% confi-
dence intervals were estimated using a Cox proportional-
hazards model. Survival time was from the date of the
first rituximab dose to date of reinfusion due to clinical
relapse. Patients with no relapse were censored at date of
last follow-up. Data analysis was carried out using Stata
13.0 (StataCorp, College Station, TX) for Windows.
Results
Twenty-five patients with MuSK MG were included in
the study: 11 were treated with protocol 4 + 2, five were
treated with protocol 1 + 1, and nine were treated with
protocol 4. Table 1 summarizes the demographic and
clinical characteristics of the three treatment groups. The
only significant difference between groups in baseline
characteristics in the univariate analyses was age at onset
(P = 0.035). Age at which rituximab was started did not
differ significantly between groups (P = 0.449). Treatment
with rituximab was associated with a significant improve-
ment in all patients, and all achieved MM or a better
MGFA PIS. After rituximab was started, other treatment,
especially prednisone, was decreased or withdrawn in all
patients (Table 2). Patients were followed up for a mean
of 5.0 years (SD 3.3).
No patient presented severe adverse events. During the
infusion, seven patients presented mild symptoms: three
of the 11 patients in the 4 + 2 protocol group (one facial
paresthesias, one fever, and one skin and mucous itch-
ing); one of the five patients in the 1 + 1 protocol group
(mild gastrointestinal symptoms); and three of the nine
patients in the protocol 4 group (two patients with skin
rash and one fatigue). All these symptoms disappeared
when premedication with antihistamine and steroid treat-
ment was given before further infusions of rituximab.
Relapse occurred in two patients in group 4 + 2, in four
patients in group 1 + 1, and in three patients in group 4,
resulting in relapse rates of 18.2%, 80%, and 33.3%, respec-
tively. The mean time to relapse was 3.5 years (SD 1.5, Min
2.5–Max 4.6), 1.1 years (SD 0.4, Min 0.7–Max 1.6), and
2.5 years (SD 1.4, Min 1.2–Max 4.1), respectively. Kaplan–
Meier estimates showed a clear difference in survival curves
among groups, with patients treated with protocol 4 + 2
having fewer relapses (log-rank test P = 0.0001). Survival
curves are shown in Figure 1.
Table 1. Demographic and clinical data of patients included in the study and comparison between groups.
4 + 2 doses (n = 11) 1 + 1 (n = 5) 4 doses (n = 9) P
Age at onset (years)
Mean (SD) 47.2 (15.7) 39.5 (17.4) 30.5 (9.6) 0.035
Min–Max 14.7–73.8 18.3–65.9 17.0–45.9
Sex (% female) 11 (100%) 4 (80%) 9 (100%) 0.200
Worst MGFA class IIIB 3 (27.3%) IIB 2 (40%) IIIB 6 (66.7%) 0.073
IVB 6 (54.5%) IIIB 1 (20%) IVB 1 (11.1%)
V 2 (18.2%) IVB 1 (20%) V 2 (22.2%)
V 1 (20%)
Age when RTX was started (years)
Mean (SD) 55.4 (12.5) 46.3 (21.9) 49.2 (16.5) 0.449
Min–Max 35.3–78.9 19.4–78.9 26.5–70.1
Best MGFA PIS CRS 5 (45.4%) CSR 1 (20%) CSR 1 (11.1%) 0.335
PR 2 (18.2%) PR 3 (60%) PR 2 (22.2%)
MM 4 (36.4%) MM 1 (20%) MM 6 (66.7%)
Follow-up (years)
Mean (SD) 6.6 (3.5) 3.5 (1.9) 4.0 (3.3) 0.114
Min–Max 1.4–11.6 1.3–6.3 1.6–11.7
MGFA PIS last visit CRS 4 (36.4%) CRS 2 (40%) CSR 1 (11.1%) 0.665
PR 1 (9.1%) PR 1 (20%) PR 2 (22.2%)
MM 6 (54.6%) MM 2 (40%) MM 6 (66.7%)
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Table 2. Previous treatments, treatment before rituximab, and treatment at last evaluation for each patient. Time regarding how long treatment
was provided both for treatment before rituximab and treatment at last visit are provided in brackets.
Patient
Rituximab
protocol Previous treatments Treatment before rituximab (treatment duration)
Treatment at last visit
(treatment duration)
1 4 + 2 Pyridostigmine,
PDN, IVIG
Pyridostigmine 300 mg per day (6 months), PDN 60 mg
per day (1 month)
None (53 months)
2 4 + 2 Pyridostigmine,
DFZ, CYA
DFZ 30 mg EOD (99 months), CYA 150 mg every 12 h
(87 months), Pyridostigmine 300 mg per day (99 months)
DFZ 6 mg EOD (61 months),
Pyridostigmine 240 mg per
day (61 months)
3 4 + 2 PDN, IVIG, CYA PDN 60 mg/5 mg EOD (4 months), CYA 100 mg every
12 h (2 months)
None (59 months)
4 4 + 2 PDN, AZA, MMF,
CYA, IVIG
PDN 65 mg EOD (48 months), CYA 150 mg per day
(9 months)
PDN 10 mg EOD (23 months)
5 4 + 2 PDN, IVEG, PLEX,
Pyridostigmine
PDN 60 mg per day (2 months) PDN 40 mg EOD (17 months)
6 4 + 2 PDN, THYM, AZA,
IVIG, CPH, CYA
Pyridostigmine if needed (38 months) (CPH abandoned
19 months before)
None (24 months)
7 4 + 2 THYM, PDN, AZA,
CPH, IVIG, MMF
MMF 2 g per day (3 months) None (96 months)
8 4 + 2 PDN, THYM, AZA, MMF,
CYA, IVIG, CPH
PDN 15 mg EOD (5 months, 245 months in total with
PDN), MMF 2 g per day (3 months)
PDN 30 mg EOD (18 months)
9 4 + 2 PDN, AZA PDN 40 mg EOD (19 months, 79 months in total with
PDN)
None
10 4 + 2 PDN, AZA, IVIG,
CYA, PLEX
PDN 30 mg EOD (18 months, 51 months in total with
PDN), CYA 125 mg per day (6 months)
Pyridostigmine if needed
(30 months)
11 4 + 2 PDN, AZA, CYA, IVIG,
Pyridostigmine
PDN 80 mg EOD (28 months), Pyridostigmine 300 mg per
day (29 months)
PDN 7 mg EOD (3 months)
12 1 + 1 Pyridostigmine, PDN, MMF PRD 60 mg EOD (1 month), Pyridostigmine if needed PDN 10 mg EOD (7 months)
13 1 + 1 PDN PDN 25 mg EOD (6 months), Pyridostigmine if needed None (12 months) (rituximab
when relapse)
14 1 + 1 PDN PDN 60 mg/30 mg EOD (4 months) None (35 months)
15 1 + 1 PDN, AZA, MMF PDN 40 mg per day (1 month, 223 months in total with
PDN)
PDN 12.5 mg per day
(29 months)
16 1 + 1 IVIG, PDN, MMF,
PLEX, CYA
PDN 45 mg EOD (47 months), CYA 100 mg every 12 h




17 4 THYM, Pyridostigmine,
PDN, TAC, PLEX
PDN 5 mg EOD (60 months), TAC 2 mg every 12 h
(10 months), Pyridostigmine 120 mg per day (96 months)
None (20 months)
18 4 PDN, THYM, IVIG, AZA PDN 20 mg per day (36 months), MMF 1 g per day
(24 months)
MMF 1.500 g per day
(30 months)
19 4 Pyridostigmine, PDN, AZA,
TAC, IVIG, PLEX
TAC 1, 5 mg every 12 h (23 months), PDN 20 mg EOD
(23 months), Pyridostigmine 180 mg per day (35 months)
CYA 125 mg every 12 h
(23 months), PDN 50 mg
EOD (23 months)
20 4 Pyridostigmine, PDN, AZA,
PLEX, IVIG, THYM
PDN 30 mg EOD (264 months), Pyridostigmine 360 mg
per day (265 months)
PDN 10 mg per day (45 months)
21 4 Pyridostigmine, PDN,
AZA, PLEX, IVIG, THYM
PDN 30 mg per day (300 months) PDN 10 mg per day (53 months)
22 4 Pyridostigmine, PDN,
AZA, PLEX
AZA 111 mg per day (60 months) None (21 months)
23 4 Pyridostigmine, PDN,
AZA, IVIG, PLEX
AZA 111 mg per day (60 months), PDN 30 mg EOD
(120 months)
PDN 10 mg EOD (26 months)
24 4 Pyridostigmine, PDN,
AZA, MMF
MMF 2.5 g per day (45 moths), PDN 30 mg/15 mg EOD
(71 months)
PDN 10 mg EOD (12 months)
25 4 PDN, MTX, AZA,
MMF, IVIG, PLEX
PDN 70 mg per day (106 months) None (116 months)
PDN, prednisone; DFZ, Deflazacort; AZA, azathioprine; MMF, Mycophenolate mofetil; CYA, cyclosporine; TAC, Tacrolimus; CPH,
cyclophosphamide; MTX, methotrexate; IVIG, intravenous immunoglobulin; PLEX, plasma exchange; THYM, thymectomy; EOD, Every other day.
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The Cox proportional-hazards regression model
showed that patients treated with protocol 1 + 1 had a
higher risk of relapse and a greater need for reinfusion
with rituximab than patients treated with protocol 4 + 2
(hazard ratio [HR] 112.8, 95% confidence interval [CI],
5.7–2250.4, P = 0.002). Patients treated with protocol 4
also showed a trend to a higher risk of relapse than
patients treated with protocol 4 + 2 (HR 9.2, 95% CI
0.9–91.8, P = 0.059) (likelihood ratio test = 15.1,
P = 0.0005).
Discussion
Rituximab has previously shown level IV evidence as a
beneficial and durable treatment option for drug-resistant
MuSK MG.17,20 Our results further add that the treatment
protocol plays a key role in reducing clinical relapse and
achieving a long-lasting response. All patients included in
this study improved after rituximab treatment and all
patients achieved MM or a better MGFA PIS and a long-
lasting response after an extended follow-up. Moreover,
prednisone and other immunosuppressive therapies were
withdrawn or tapered to lower doses in all cases. Ritux-
imab was also found to be safe as no patient developed
severe side effects. The frequency of mild-moderate
adverse events did not differ between the three groups.
This finding is of particular note because most patients
had been treated previously with two or more immuno-
suppressive therapies. Close follow-up is recommended,
however, as several cases of side effects of rituximab have
been reported in patients with MG.32
Various protocols of rituximab have been published to
treat patients with MuSK MG, and relapse rates and
durability of response have differed.17,20 As no infusion
regimen has yet been standardized in this setting, we
compared the clinical response of 25 MuSK MG patients
treated with three different rituximab protocols. Because
all patients responded to the drug, the primary effective-
ness endpoint chosen was the appearance of a clinical
relapse requiring a further infusion of rituximab. Based
Figure 1. Kaplan–Meier survival curves for relapse in each group of patients with MuSK MG according to the rituximab protocol followed:
(4 + 2) 375 mg/m2 every week for four consecutive weeks and then monthly for the next 2 months; (1 + 1) two 1 g doses separated by
2 weeks; and (4) 375 mg/m2 every week for four consecutive weeks.
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on Kaplan–Meier estimates, the most efficient protocol
was the 4 + 2 protocol. It showed the lowest relapse rate
(18.2%) and the longest time to relapse after an extended
follow-up period. The Cox proportional-hazards regres-
sion confirmed that patients treated with protocol 1 + 1
had a significantly higher risk of relapse and greater need
for reinfusion with rituximab than patients receiving the
4 + 2 protocol. Patients treated with the protocol based
on four doses also showed a trend toward a significantly
higher risk of relapse than those treated with protocol
4 + 2.
Although prominent B-cell pathology has been
described in MuSK MG,33–35 the mechanism by which
IgG4 antibodies are produced remains unclear. Rituximab
works by depleting pre-B cells and mature and memory B
cells from the circulation. Exactly how this leads to anti-
body reduction, however, is still to be determined as
B-cell populations that do not express CD20 produce a
considerable portion of circulating immunoglobulin.36
Why some patients relapse and other do not is unclear. A
recent study of autoantibody-producing cells during dis-
ease relapse in three MuSK MG subjects who had previ-
ously achieved rituximab-induced remission revealed
autoantibody-expressing CD27+ B plasmablasts within the
reconstituted repertoire during relapse but not during
remission or in controls.37 The authors proposed that
MuSK-specific memory cells continuously supply a popu-
lation of short-lived, autoantibody-secreting plasmablasts,
and suggested that rituximab works by indirectly deplet-
ing the CD20 plasmablast population by diminishing
CD20+ memory B cells. Alternatively, they hypothesized
that rituximab could work by directly depleting a fraction
of plasmablasts that may be CD20+.
In our study, we observed that all patients with MuSK
MG treated with rituximab had a beneficial response. How-
ever, the relapse rate differed depending on the posology
used, with the 4 + 2 protocol being the most effective in
terms of response durability. We hypothesize that this proto-
col is more efficacious in depleting the pool of plasmablasts-
progenitor CD20+ memory B cells or the subset of CD20+
plasmablasts than the two other protocols followed. Further
studies are needed to confirm this hypothesis.
The main limitation of our study is the small number
of patients. MuSK MG is a rare disorder, however, and as
not all cases are severe or drug-resistant, rituximab is not
always required. The strengths of the study are the signifi-
cant results in the statistical analysis, and particularly the
long clinical follow-up, with an overall mean of 5 years.
In summary, our findings add to the evidence that
rituximab is effective and safe in the treatment of MuSK
MG. We recommend treating patients with a sole induc-
tion regimen of rituximab following the protocol 4 + 2
(375 mg/m2 every week for 4 consecutive weeks and then
monthly for the next 2 months), since this protocol
ensures a minimal rate of clinical relapse and a long-last-
ing response to rituximab. To minimize potential adverse
events, we recommend re-treating patients with rituximab
in cases of clinical relapse only.
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